Combination chemotherapy in feline lymphoma: Treatment outcome, tolerability, and duration in 23 cats

Journal of Veterinary Internal Medicine

Volumn 22, Issue 2, 2008, Pages 394-400

  Simon, Daniela ^a   Eberle, N ^a   Laacke Singer, L ^a   Nolte, I ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Feline immunodeficiency virus feline leukemia virus; Lymphosarcoma; Remission; Survival; Toxicosis

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; LYMPHOMA; MALE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CAT DISEASES; CATS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; LYMPHOMA; MALE; METHOTREXATE; PREDNISOLONE; TREATMENT OUTCOME; VINCRISTINE;

ANIMALIA; FELIDAE;

EID: 42449126714     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0057.x     Document Type: Article

References (30)

1. Dorn CR, Taylor DON, Hibbard HH. Epozootiologic characteristics of canine and feline leukaemia and lymphoma. Am J Vet Res 1967;28:993-1001.
2. Hardy WD. Hematopoietic tumors of cats. J Am Anim Hosp Assoc 1981;17:921-940.
3. Schneider R. Comparison of age- and sex-specific incidence rate patterns of the leukaemia complex in the cat and dog. J Natl Cancer Inst 1983;70:971-977.
4. Louwerens M, London CA, Pedersen NC, et al. Feline lymphoma in the post-feline leukaemia virus era. J Vet Intern Med 2005;19:329-335.
5. Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine and prednisone: II. Treatment of cats. J Am Anim Hosp Assoc 1983;19:166-172.
6. Jeglum KA, Whereat A, Young K. Chemotherapy of lymphoma in 75 cats. J Am Vet Med Assoc 1987;190:174-178.
7. Mooney SC, Hayes AA, Matus RE, et al. Treatment and prognostic factors in lymphoma in cats: 103 cases (1977-1981). J Am Vet Med Assoc 1989;194:696-699.
8. Mahony OM, Moore AS, Cotter SM, et al. Alimentary lymphoma in cats: 28 cases (1988-1993). J Am Vet Med Assoc 1995;207:1593-1597.
9. Moore AS, Cotter SM, Frimberger AE, et al. A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma. J Vet Intern Med 1996;10:372-375.
10. Vail DM, Moore AS, Ogilvie GK, Volk LM. Feline lymphoma (145 cases): Proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. J Vet Intern Med 1998;12:349-354.
11. Link M, Hirschberger J. Feline lymphoma: Treatment results and prognostic factors (18 cats). Tierärztl Prax 2000;28:87-93.
12. Malik R, Gabor LJ, Foster SF, et al. Therapy of Australian cats with lymphosarcoma. Aust Vet J 2001;79:808-817.
13. Kristal O, Lana SE, Ogilvie GK, et al. Single agent chemotherapy with doxorubicin for feline lymphoma: A retrospective study of 19 cases (1994-1997). J Vet Intern Med 2001;15:125-130.
14. Teske E, van Straten G, van Noort R, et al. Chemotherapy with cyclophosphamid, vincristine, and prednisolon (COP) in cats with malignant lymphoma: New results with an old protocol. J Vet Intern Med 2002;16:179-186.
15. Milner RJ, Peyton J, Cooke K, et al. Response rates and survival times for cats with malignant lymphoma treated with the University of Wisconsin-Madison chemotherapy protocol: 38 cases (1996-2003). J Am Vet Med Assoc 2005;227:1118-1122.
16. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124.
17. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
18. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
19. Morrison-Collister KE, Rassnick KM, Northrup NC, et al. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma. Vet Comp Oncol 2003;1:180-190.
20. Simon D, Nolte I, Eberle N, Abbrederis N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2000;20:948-954.
21. Vail DM. Feline lymphoma and leukemia. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology. St. Louis, MO: Saunders; 2007:733-756.
22. Mooney SC, Hayes AA. Lymphoma in the cat: An approach to diagnosis and management. Semin Vet Med Surg (Small Anim) 1986;1:51-57.
23. Veterinary Co-Operative Oncology Group. Veterinary Co-Operative Oncology Group - Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
24. Gabor LJ, Malik R, Canfield PJ. Clinical and anatomical features of lymphosarcoma in 118 cats. Aust Vet J 1998;76:725-732.
25. Gabor LJ, Jackson ML, Trask B, et al. Feline leukaemia virus status of Australian cats with lymphosarcoma. Aust Vet J 2001;79:476-481.
26. Zwahlen CH, Lucroy MD, Kraegel SA, et al. Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases (1993-1997). J Am Vet Med Assoc 1998;213:1144-1149.
27. Shelton GH, Grant CK, Cotter SM, et al. Feline immunodeficiency virus and feline leukemia virus infections and their relationships to lymphoid malignancies in cats: A retrospective study (1968-1988). J Acquir Immune Defic Syndr 1990;3:623-630.
28. Callanan JJ, Jones BA, Irvine J, et al. Histologic classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections. Vet Pathol 1996;33:264-272.
29. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-1632.
30. Glasgow RE, Magid DJ, Beck A, et al. Practical clinical trials for translating research to practice: Design and measurement recommendations. Med Care 2005;43:551-557.